{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T07:31:34Z","timestamp":1789716694238,"version":"4.0.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.clml.2018.05.007","type":"journal-article","created":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T20:17:55Z","timestamp":1527193075000},"page":"501-507","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Optimal Management of Histone Deacetylase Inhibitor-Related Adverse Events in Patients With Multiple Myeloma: A Focus on Panobinostat"],"prefix":"10.1016","volume":"18","author":[{"given":"Jamie D.","family":"Cavenagh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6553-4618","authenticated-orcid":false,"given":"Rakesh","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2018.05.007_bib1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.05.007_bib2","first-page":"7","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2018.05.007_bib3","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.007_bib4","series-title":"Cancer: Principles & Practice of Oncology","first-page":"2305","article-title":"Plasma cell neoplasms","author":"Munshi","year":"2008"},{"key":"10.1016\/j.clml.2018.05.007_bib5","first-page":"301","article-title":"Multiple myeloma: charging toward a bright future","volume":"57","author":"Katzel","year":"2007","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2018.05.007_bib6","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.05.007_bib7","first-page":"1431","article-title":"Treatment-related symptom management in patients with multiple myeloma: a review","volume":"23","author":"Colson","year":"2015","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clml.2018.05.007_bib8","series-title":"Farydak (panobinostat) [prescribing information]","year":"2016"},{"key":"10.1016\/j.clml.2018.05.007_bib9","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial","volume":"15","author":"San-Miguel","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2018.05.007_bib10","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.2143.2143","article-title":"Effects of bone marrow infiltration by multiple myeloma on erythropoiesis","volume":"126","author":"Moyo","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.007_bib11","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3816\/CLM.2009.n.056","article-title":"Treatment of multiple myeloma: a comprehensive review","volume":"9","author":"Kyle","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.clml.2018.05.007_bib12","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1182\/blood-2010-11-318055","article-title":"Deciphering the molecular and biological processes that mediate histone deacetylase inhibitor-induced thrombocytopenia","volume":"117","author":"Bishton","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.007_bib13","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.exphem.2012.02.004","article-title":"Panobinostat (LBH589)-induced acetylation of tubulin impairs megakaryocyte maturation and platelet formation","volume":"40","author":"Iancu-Rubin","year":"2012","journal-title":"Exp Hematol"},{"key":"10.1016\/j.clml.2018.05.007_bib14","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/leu.2010.262","article-title":"Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes","volume":"25","author":"Giver","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.05.007_bib15","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood-2013-01-481325","article-title":"PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma","volume":"122","author":"Richardson","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.007_bib16","series-title":"Farydak (panobinostat) [summary of product characteristics]","year":"2017"},{"key":"10.1016\/j.clml.2018.05.007_bib17","doi-asserted-by":"crossref","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","article-title":"Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002\u2014Medical Research Council Adult Leukaemia Working Party","volume":"23","author":"Augustson","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.05.007_bib18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2018.05.007_bib19","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1600-0609.2006.00739.x","article-title":"Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European Cancer Anaemia Survey","volume":"77","author":"Birgegard","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2018.05.007_bib20","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2001.19.11.2865","article-title":"Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial","volume":"19","author":"Littlewood","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.05.007_bib21","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1200\/JCO.2002.08.131","article-title":"Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies","volume":"20","author":"Osterborg","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.05.007_bib22","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1046\/j.1365-2141.2003.04448.x","article-title":"Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study","volume":"122","author":"Hedenus","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.05.007_bib23","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ejca.2006.10.014","article-title":"EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update","volume":"43","author":"Bokemeyer","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2018.05.007_bib24","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1182\/blood-2010-08-300541","article-title":"American Society of Hematology\/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer","volume":"116","author":"Rizzo","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.007_bib25","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/S0140-6736(09)60502-X","article-title":"Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials","volume":"373","author":"Bohlius","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2018.05.007_bib26","first-page":"CD003407","article-title":"Erythropoietin or darbepoetin for patients with cancer","volume":"12","author":"Tonia","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clml.2018.05.007_bib27","author":"National Comprehensive Cancer Network"},{"key":"10.1016\/j.clml.2018.05.007_bib28","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1600-0609.2012.01831.x","article-title":"Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population-based study using the PROFILES registry","volume":"89","author":"Mols","year":"2012","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2018.05.007_bib29","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2141.2011.08574.x","article-title":"Guidelines for supportive care in multiple myeloma 2011","volume":"154","author":"Snowden","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.05.007_bib30","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1093\/annonc\/mdi267","article-title":"Screening studies for fatigue and laboratory correlates in cancer patients undergoing treatment","volume":"16","author":"Shafqat","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2018.05.007_bib31","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/(SICI)1097-0142(19970501)79:9<1717::AID-CNCR12>3.0.CO;2-0","article-title":"Aerobic exercise in the rehabilitation of cancer patients after high dose chemotherapy and autologous peripheral stem cell transplantation","volume":"79","author":"Dimeo","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2018.05.007_bib32","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/00002820-200310000-00012","article-title":"Feasibility of exercise during treatment for multiple myeloma","volume":"26","author":"Coleman","year":"2003","journal-title":"Cancer Nurs"},{"key":"10.1016\/j.clml.2018.05.007_bib33","author":"National Comprehensive Cancer Network"},{"key":"10.1016\/j.clml.2018.05.007_bib34","doi-asserted-by":"crossref","first-page":"e572","DOI":"10.1016\/S2352-3026(16)30165-X","article-title":"Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1\/2 trial","volume":"3","author":"Popat","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2018.05.007_bib35","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.4530.4530","article-title":"A\u00a0phase I\/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed\/refractory multiple myeloma (MM): final analysis of second dose expansion","volume":"128","author":"Berdeja","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.007_bib36","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.32.32","article-title":"Phase I study of the combination of carfilzomib and panobinostat for patients with relapsed and refractory myeloma: a Multiple Myeloma Research Consortium (MMRC) clinical trial","volume":"124","author":"Kaufman","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.007_bib37","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1182\/blood.V120.21.4081.4081","article-title":"Phase 1\/1b study of the efficacy and safety of the combination of panobinostat\u00a0+ carfilzomib in patients with relapsed and\/or refractory multiple myeloma","volume":"120","author":"Shah","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.007_bib38","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.4221.4221","article-title":"A\u00a0phase I study of ixazomib in combination with panobinostat and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"126","author":"Reu","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.007_bib39","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.4226.4226","article-title":"A\u00a0phase II study of panobinostat with lenalidomide and weekly dexamethasone in myeloma","volume":"126","author":"Chari","year":"2015","journal-title":"Blood"},{"issue":"suppl 2","key":"10.1016\/j.clml.2018.05.007_bib40","first-page":"158","article-title":"A\u00a0phase IB study evaluating the combination of oral panobinostat (LBH589) with lenalidomide and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma","volume":"95","author":"Mateos","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.05.007_bib41","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.1826.1826","article-title":"Bortezomib (Velcade), thalidomide, dexamethasone and panobinostat (VTD-P) is a safe, well tolerated and efficacious regimen for patients with relapsed multiple myeloma: preliminary results of the MUK-six trial","volume":"126","author":"Popat","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.007_bib42","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI69738","article-title":"New and emerging HDAC inhibitors for cancer treatment","volume":"124","author":"West","year":"2014","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.clml.2018.05.007_bib43","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1158\/1078-0432.CCR-16-2526","article-title":"Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma","volume":"23","author":"Vogl","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2018.05.007_bib44","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S1470-2045(16)30375-8","article-title":"Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial","volume":"17","author":"Yee","year":"2016","journal-title":"Lancet Oncol"},{"issue":"suppl","key":"10.1016\/j.clml.2018.05.007_bib45","article-title":"Ricolinostat (ACY-1215), the first selective HDAC6 inhibitor, combined with pomalidomide and dexamethasone shows promising early phase 2 results in relapsed-and-refractory multiple myeloma: ACE-MM-102","volume":"101","author":"Raje","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.05.007_bib46","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1182\/blood.V128.22.3307.3307","article-title":"Selective HDAC6 inhibitor ACY-241, an oral tablet, combined with pomalidomide and dexamethasone: safety and efficacy of escalation and expansion cohorts in patients with relapsed or relapsed-and-refractory multiple myeloma (ACE-MM-200 study)","volume":"128","author":"Niesvizky","year":"2016","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018301800?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018301800?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:30:54Z","timestamp":1761870654000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265018301800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S2152265018301800"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2018.05.007","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimal Management of Histone Deacetylase Inhibitor-Related Adverse Events in Patients With Multiple Myeloma: A Focus on Panobinostat","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2018.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}